KRAS mutations are established biomarkers for predicting the poor efficacy of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in patients with stage IV CRC [2, 5, 11], but the prognostic relevance of KRAS mutations remains controversial [12–16]. This evidence concerns the gene KRAS and colorectal carcinoma.